500614 Sigma-AldrichSurvivin Inhibitor III, LLP-3 - Calbiochem

Survivin Inhibitor III, LLP-3 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

SDS
References
Data Sheet

Synonyms: 4-(3,5-bis(Benzyloxy)phenyl)-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, Survivin-Ran Interaction Blocker, LLP3

Primary Target: survivin

Recommended Products

Overview

Replacement Information

Key Specifications Table

Empirical Formula
C₃₂H₂₃ClN₂O₄

Pricing & Availability

Catalog Number	Availability	Packaging	Qty/Pack	Price	Quantity
5.00614.0001	Retrieving availability... — Limited Availability Stocked Discontinued Limited Quantities Available Available Login to See Inventory Stocked Limited Availability Stocked Remaining : Will advise Remaining : Will advise Will advise Contact Customer Service Contact Customer Service Contact Customer Service Contact Customer Service	Glass bottle	10 mg	Retrieving price... Price could not be retrieved Minimum Quantity is a multiple of Maximum Quantity is Upon Order Completion More Information You Saved () — Request Pricing Login to See Your Pricing	Check Availability —	Add To Favorites Add To Favorites Added To My Favorites

Description
Overview	A cell-permeable, dihydropyridinone compound that selectively disrupts survivin-Ran interaction in cell-free binding assays (IC₅₀ <0.3 µM) and in U87 glioma cells (by 55% in 24 h; 20 µM) via direct binding at survivin protein-protein interaction interface, while exhibiting much reduced or little potency against survivin-Smac/DIABLO, survivin-survivin, or XIAP-Smac/DIABLO interaction. LLP-3 treatment abrogates neurosphere formation in GMB cultures (IC₅₀ ≤35 µM) by selectively depleting CD133+ GSC population via apoptosis induction. TMZ (Cat. No. 500609), in comparison, enriches GMB GSC population by preferentially eradicating non-GSC population. LLP-3 is also efficacious in treating human GMB xenograft in mice in vivo (25 mg/kg/day via i.p.). Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
Catalogue Number	500614
Brand Family	Calbiochem®
Synonyms	4-(3,5-bis(Benzyloxy)phenyl)-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, Survivin-Ran Interaction Blocker, LLP3

References
References	Guvenc, H., et al. 2013. Clin. Cancer Res. 19, 1.

Product Information
Form	Yellow solid
Hill Formula	C₃₂H₂₃ClN₂O₄
Chemical formula	C₃₂H₂₃ClN₂O₄
Reversible	Y
Structure formula Image
Quality Level	MQ100

Applications

Biological Information
Primary Target	survivin
Purity	≥99% by HPLC

Physicochemical Information
Cell permeable	Y

Dimensions

Materials Information

Toxicological Information

Safety Information according to GHS

Safety Information

Product Usage Statements

Storage and Shipping Information
Ship Code	Ambient Temperature Only
Toxicity	Standard Handling
Storage	+2°C to +8°C
Protect from Light	Protect from light
Do not freeze	Ok to freeze
Special Instructions	Following reconstitution, aliquot and freeze (-20°C. Stock solutions are stable for up to 6 months at -20°C.

Packaging Information
Packaged under inert gas	Packaged under inert gas

Transport Information

Supplemental Information

Specifications

Documentation

Survivin Inhibitor III, LLP-3 - Calbiochem SDS

Title
Safety Data Sheet (SDS)

References

Reference overview
Guvenc, H., et al. 2013. Clin. Cancer Res. 19, 1.

Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision	10-May-2013 JSW
Synonyms	4-(3,5-bis(Benzyloxy)phenyl)-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, Survivin-Ran Interaction Blocker, LLP3
Description	A cell-permeable, bioavailable dihydropyridinone compound that selectively disrupts survivin-Ran interaction (IC₅₀ <0.3 µM) in cell-free binding assays and in cells (by 55% in U87 glioma cells after 24 h 20 µM treatment) via direct binding at survivin protein-protein interaction interface, while exhibiting much reduced or little potency against survivin-Smac/DIABLO, survivin-survivin, or XIAP-Smac/DIABLO interaction. Survivin and Ran expressions are reported to be upregulated in GSCs (glioma stem cells; CD133-/Nestin-/Sox2-/MELK-positive and TuJ1-negative) when compared to non-GSC (TuJ1-positive) population in patients-derived GMB (Glioblastoma multiforme) cultures and LLP-3 treatment abrogates neurosphere formation in GMB cultures (IC₅₀ ≤35 µM) by selectively depleting CD133+ GSC population (89% drop of CD133+ population vs. 33% drop in CD133- population in GBM528 cultures after 7 d 25 µM treatment) via apoptosis induction. TMZ treatment, in comparison, results in GMB GSC population enrichment by preferentially eradicating non-GSC population. LLP-3 is also efficacious in treating human GMB xenograft in mice in vivo (median survival days = 35 vs. 15.5 with or without treatment; 25 mg/kg/day via i.p.; 5 d/wk for 2 wks starting d10 post GMB xenograft). TMZ (Cat. No. 500609), in comparison, enriches GMB GSC population by preferentially eradicating non-GSC population.
Form	Yellow solid
Intert gas (Yes/No)	Packaged under inert gas
Chemical formula	C₃₂H₂₃ClN₂O₄
Structure formula
Purity	≥99% by HPLC
Solubility	DMSO (50 mg/ml)
Storage	+2°C to +8°C Protect from light
Do Not Freeze	Ok to freeze
Special Instructions	Following reconstitution, aliquot and freeze (-20°C. Stock solutions are stable for up to 6 months at -20°C.
Toxicity	Standard Handling
References	Guvenc, H., et al. 2013. Clin. Cancer Res. 19, 1.